BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.
In the News
Researchers Publish Two New Methods for Analysis of CRISPR Off-Target Effects
Two studies published simultaneously in Nature Methods yesterday describe new methods for analyzing the off-target effects of CRISPR/Cas-9 genome editing. One method identifies off-target mutations associated with cell-type-specific SNPs, while the other detects potential off-target cleavage sites.
From corn to cattle, gene editing is about to supercharge agriculture
Corn isn’t the sexiest crop but it’s one of the most important. It’s the most abundant grain on Earth, used as food and biofuel around the globe. In ancient times, Mesoamericans thrived on it, waged wars over it. Their myths claimed corn was the matter from which gods created mankind itself.